Key facts
- This page summarizes BKB Growth Investments, LLC's Form 3 filing for Verrica Pharmaceuticals Inc. (VRCA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Jan 2026, 16:23.
BKB Growth Investments, LLC - 25 Nov 2025 Form 3 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- VRCA
- Reported as of
- 25 Nov 2025
- Net transaction value
- $0
- Reporting owner signature
- BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
BKB Growth Investments, LLC filed Form 3 for Verrica Pharmaceuticals Inc. (VRCA) on 26 Jan 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002101167
Primary reporting owner
BKB Growth Investments, LLC
- Relationship
- 10%+ Owner
- Address
- C/O TIGER LILY CAPITAL, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE
- Signature
- BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager
- Signature date
- 26 Jan 2026
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRCA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,348,372
- Date
- 25 Nov 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRCA
holding
Derivative
Series B Warrants (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 224,719
- Exercise price
- $1.34
- Footnotes
- F1, F2
VRCA
holding
Derivative
Series C Warrants (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 25 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 687,690
- Exercise price
- $6.32
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Immediately exercisable.
Footnote F2
The Reporting Person will not be entitled to exercise any portion of a Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Footnote F3
The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.